A Study to Determine the Feasibility of Treating Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Using Autologous NY-ESO-1 Specific CD8+ T Cells With Cyclophosphamide Pre-conditioning But Without the Use of IL-2

This phase I trial studies the side effects and best way to give NY-ESO-1 specific T cells after cyclophosphamide in treating patients with advanced synovial sarcoma or myxoid/round cell liposarcoma. Placing a gene that has been created in the laboratory into white blood cells may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving NY-ESO-1 specific T cells with cyclophosphamide may kill more tumor cells.

开始日期2014-07-01

申办/合作机构

Fred Hutchinson Cancer Research Center

[+1]

100 项与 Autologous anti-NY-ESO1 T-cell receptor gene-engineered peripheral blood lymphocytes(Roswell Park Comprehensive Cancer Center) 相关的临床结果

登录后查看更多信息

100 项与 Autologous anti-NY-ESO1 T-cell receptor gene-engineered peripheral blood lymphocytes(Roswell Park Comprehensive Cancer Center) 相关的转化医学

登录后查看更多信息

100 项与 Autologous anti-NY-ESO1 T-cell receptor gene-engineered peripheral blood lymphocytes(Roswell Park Comprehensive Cancer Center) 相关的专利（医药）

登录后查看更多信息

项与 Autologous anti-NY-ESO1 T-cell receptor gene-engineered peripheral blood lymphocytes(Roswell Park Comprehensive Cancer Center) 相关的文献（医药）

2018-09-04·Cold Spring Harbor perspectives in biology

Is a Human CD8 T-Cell Vaccine Possible, and if So, What Would It Take? CD8 T-Cell Vaccines: To B or Not to B?

Review

作者: Beura, Lalit K ; Jameson, Stephen C ; Masopust, David

Although CD8 T-cell vaccines do not have the record of success of humoral-mediated vaccines, they do not receive the same degree of effort. Many diseases, including malaria, tuberculosis, and acquired immune deficiency syndrome (AIDS) have not yielded to vaccines, and intrinsic barriers may impede approaches limited solely to generating antibodies. Moreover, population growth and modernization are driving an increased pace of new emerging global health threats (human immunodeficiency virus [HIV] is a recent example), which will create unpredictable challenges for vaccinologists. Vaccine-elicited CD8 T cells may contribute to protective modalities, although their development will require a more thorough understanding of CD8 T-cell biology, practices for manufacturing and delivering CD8 T-cell-eliciting vectors that have acceptable safety profiles, and, ultimately, the political will and faith of those that make vaccine research funding decisions.

2018-09-01·Cold Spring Harbor Perspectives in Biology1区 · 生物学

Is a Human CD8 T-Cell Vaccine Possible, and if So, What Would It Take?

1区 · 生物学

Review

作者: McMichael, Andrew J

Vaccines that stimulate CD8⁺ T cells could clear early virus infection or control ongoing infection and prevent disease. This could be valuable to combat human immunodeficiency virus type 1 (HIV-1) where it has not yet been possible to generate broadly reacting neutralizing antibodies with a vaccine. However, HIV-1 vaccines aimed at stimulating CD8⁺ T cells have had no success. In contrast, a cytomegalovirus vectored simian immunodeficiency virus (SIV) vaccine enabled clearance of early SIV infection. This may open the door to the design of an effective HIV vaccine.

2018-09-01·Cold Spring Harbor Perspectives in Biology1区 · 生物学

Is a Human CD8 T-Cell Vaccine Possible, and if So, What Would It Take?

1区 · 生物学

Review

作者: Sztein, Marcelo B

Although induction of CD8⁺ responses is widely accepted as critical in clearing viral infections and necessary for effective vaccines against viruses, much less is known regarding the role of these cells in bacterial and other infections, particularly those that enter the host via the gastrointestinal tract. In this commentary, I discuss the likelihood that CD8⁺ responses are also important in protection from intestinal Gram-negative bacteria, as well as the many factors that should be taken into consideration during the development of vaccines, based on eliciting long-term protection predominantly mediated by CD8⁺ responses against these organisms.

100 项与 Autologous anti-NY-ESO1 T-cell receptor gene-engineered peripheral blood lymphocytes(Roswell Park Comprehensive Cancer Center) 相关的药物交易

登录后查看更多信息